INTRODUCTION

Wayne Godfrey is a physician scientist with over 25 years clinical and drug development experience. In the biotech industry, he has worked on multiple phase 1 through 4 clinical trial programs, lead clinical teams, contributed to FDA approvals, and held management and leadership roles.

Dr. Godfrey started his biotech career at Dendreon, supporting the development of the first FDA approved cellular immunotherapy, Provenge® (sipuleucel-T), for prostate cancer. Subsequently he rose to CMO and lead clinical development at BN Immunotherapeutics, and Etubics, both viral based cancer vaccine companies, targeting multiple solid tumors. He has also initiated and directed late-stage pivotal trials which lead to FDA approval, Zydelig® (idelalisib) at Gilead sciences, and trials which contributed to supplemental FDA approvals of Yescarta® (axi-cel) at Kite Pharma, with both companies programs for Non-Hodgkin Lymphoma. Later he initiated First in Human clinical trial programs at IGM Biosciences as VP, and Janux Therapeutics as CMO, both companies developing T cell engaging bispecific antibodies for cancer.

Dr. Godfrey has had a career long interest in cancer immunology and immunotherapy. He earned a B.A. in biochemistry and molecular biology from UC Santa Barbara, an M.S. in biology from Stanford University, and an M.D. from Washington University School of Medicine in St. Louis. Dr. Godfrey completed his internal medicine residency and fellowships in clinical immunology, hematology, and bone marrow transplantation at Stanford University. At Stanford Blood Center, he also did 6 years postdoctoral research identifying OX40-ligand, and human OX40 receptor, and characterizing this T cell co-stimulation system. He than became faculty at University of Minnesota Bone Marrow Transplant program for 5 years, culturing and characterizing human Treg cells, for initiating clinical trials to prevent Graft versus Host disease.